ema glp-1 vision loss recommendation november 2025 Eye Condition a 'Very Rare' Side Effect of Semaglutide, Says Exploring the Side Effects of

See how RYBELSUS performed in the PIONEER 3 Trial

This Canadian development could have broader implications across North America, potentially influencing how metabolic health treatments are delivered and priced in the future

What companies are topping biotech IPOs in 2026?ParabilisMedicines with a focus on alpha-helical peptides andKaileraTherapeutics specializing in GLP-1s and related drugs for obesity are leading the way

Different weight regain was observed in subjects with different characteristics

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to report from the RAND Education and Labor division

elegans, by promoting calcium-dependent binding of APTF-2 to the glp-1 promoter.